Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
Open Access
- 22 September 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11166
Abstract
Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.Keywords
This publication has 86 references indexed in Scilit:
- The GM–CSF/IL‐3/IL‐5 cytokine receptor family: from ligand recognition to initiation of signalingImmunological Reviews, 2012
- Structural basis of interleukin‐5 dimer recognition by its α receptorProtein Science, 2012
- IL-5- and eosinophil-mediated inflammation: from discovery to therapyInternational Immunology, 2009
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaNew England Journal of Medicine, 2009
- Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitisAllergy, 2005
- Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and DegranulationJournal of Experimental Medicine, 1998
- Critical proline residues of the cytoplasmic domain of the IL-5 receptor α chain and its function in IL-5-mediated activation of JAK kinase and STAT5International Immunology, 1996
- IL-5-Deficient Mice Have a Developmental Defect in CD5+ B-1 Cells and Lack Eosinophilia but Have Normal Antibody and Cytotoxic T Cell ResponsesImmunity, 1996
- IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases.Journal of Experimental Medicine, 1994
- Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion SurfaceScience, 1985